Strain differences in contact hypersensitivity reaction to dinitrochlorobenzene (DNCB) in rats. 2015

Aleksandra Popov Aleksandrov, and Ivana Mirkov, and Jelena Demenesku, and Marina Ninkov, and Lidija Zolotarevski, and Dragan Kataranovski, and Milena Kataranovski
Department of Ecology, Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Bulevar Despota Stefana 142, 11000 Belgrade, Serbia.

Genetic factors are among the most important determinants of susceptibility to induction of allergic contact dermatitis. A limited number of studies of experimental contact hypersensitivity (CHS) in animals has shown differences in the severity of CHS; however, the underlying mechanisms are unknown. In this study comparative analysis of CHS to low and high dinitrochlorobenzene (DNCB) doses regimen of sensitization/challenge in inbred Dark Agouti (DA) and Albino Oxford (AO) rats was examined. Basic aspects of draining lymph node (dLN) activity (cellularity, proliferation), proinflammatory (IFN-γ, IL-17) and anti-inflammatory (IL-10) cytokine gene expression and production, as well as IL-12 and IL-23 subunits mRNA expression, were examined in challenge and sensitization phase of CHS reaction. Lower (compared to DA) intensity of CHS in AO rats was associated with lack of (or negligible) dLN responses in challenge phase (ex vivo, hapten- or IL-2-stimulated cell proliferation and proinflammatory cytokine mRNA and production levels) but with lack of changes in IL-10 response. Less pronounced dLN activity of sensitized animals of this strain was observed as well. Higher proliferative activity and more pronounced proinflammatory cytokine response during challenge and sensitization phase suggest these activities as underlying mechanisms of higher susceptibility of DA rats to CHS response to DNCB.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008297 Male Males
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004137 Dinitrochlorobenzene A skin irritant that may cause dermatitis of both primary and allergic types. Contact sensitization with DNCB has been used as a measure of cellular immunity. DNCB is also used as a reagent for the detection and determination of pyridine compounds. 1-Chloro-2,4-Dinitrobenzene,2,4-Dinitrochlorobenzene,Benzene, 1-Chloro-2,4-Dinitro-,Chlorodinitrobenzene,DNCB,1 Chloro 2,4 Dinitrobenzene,2,4 Dinitrochlorobenzene
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D016753 Interleukin-10 A cytokine produced by a variety of cell types, including T-LYMPHOCYTES; MONOCYTES; DENDRITIC CELLS; and EPITHELIAL CELLS that exerts a variety of effects on immunoregulation and INFLAMMATION. Interleukin-10 combines with itself to form a homodimeric molecule that is the biologically active form of the protein. IL-10,CSIF-10,Cytokine Synthesis Inhibitory Factor,IL10,Interleukin 10

Related Publications

Aleksandra Popov Aleksandrov, and Ivana Mirkov, and Jelena Demenesku, and Marina Ninkov, and Lidija Zolotarevski, and Dragan Kataranovski, and Milena Kataranovski
March 1989, The British journal of dermatology,
Aleksandra Popov Aleksandrov, and Ivana Mirkov, and Jelena Demenesku, and Marina Ninkov, and Lidija Zolotarevski, and Dragan Kataranovski, and Milena Kataranovski
January 1966, International archives of allergy and applied immunology,
Aleksandra Popov Aleksandrov, and Ivana Mirkov, and Jelena Demenesku, and Marina Ninkov, and Lidija Zolotarevski, and Dragan Kataranovski, and Milena Kataranovski
January 1979, Voprosy onkologii,
Aleksandra Popov Aleksandrov, and Ivana Mirkov, and Jelena Demenesku, and Marina Ninkov, and Lidija Zolotarevski, and Dragan Kataranovski, and Milena Kataranovski
January 1968, La Presse medicale,
Aleksandra Popov Aleksandrov, and Ivana Mirkov, and Jelena Demenesku, and Marina Ninkov, and Lidija Zolotarevski, and Dragan Kataranovski, and Milena Kataranovski
September 1972, Pediatria polska,
Aleksandra Popov Aleksandrov, and Ivana Mirkov, and Jelena Demenesku, and Marina Ninkov, and Lidija Zolotarevski, and Dragan Kataranovski, and Milena Kataranovski
October 1978, Wiadomosci lekarskie (Warsaw, Poland : 1960),
Aleksandra Popov Aleksandrov, and Ivana Mirkov, and Jelena Demenesku, and Marina Ninkov, and Lidija Zolotarevski, and Dragan Kataranovski, and Milena Kataranovski
October 1984, Allergy,
Aleksandra Popov Aleksandrov, and Ivana Mirkov, and Jelena Demenesku, and Marina Ninkov, and Lidija Zolotarevski, and Dragan Kataranovski, and Milena Kataranovski
January 1997, Acta chirurgica Hungarica,
Aleksandra Popov Aleksandrov, and Ivana Mirkov, and Jelena Demenesku, and Marina Ninkov, and Lidija Zolotarevski, and Dragan Kataranovski, and Milena Kataranovski
January 1986, Neoplasma,
Aleksandra Popov Aleksandrov, and Ivana Mirkov, and Jelena Demenesku, and Marina Ninkov, and Lidija Zolotarevski, and Dragan Kataranovski, and Milena Kataranovski
August 1974, Bollettino della Societa italiana di biologia sperimentale,
Copied contents to your clipboard!